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Summary
Background Previous community-randomised trials of interventions to control sexually transmitted infections (STIs) 
have involved rural settings, were rarely multicomponent, and had varying results. We aimed to assess the eﬀ ect of a 
multicomponent intervention on curable STIs in urban young adults and female sex workers (FSWs).
Methods In this community-randomised trial, baseline STI screening was done between August, and November, 
2002, in random household samples of young adults (aged 18–29 years) and in FSWs in Peruvian cities with more 
than 50 000 inhabitants. Geographically separate cities were selected, matched into pairs, and randomly allocated to 
intervention or control groups with an S-PLUS program. Follow-up surveys of random samples were done after 
2 years and 3 years. The intervention comprised four modalities: strengthened STI syndromic management by 
pharmacy workers and clinicians; mobile-team outreach to FSWs for STI screening and pathogen-speciﬁ c treatment; 
periodic presumptive treatment of FSWs for trichomoniasis; and condom promotion for FSWs and the general 
population. Individuals in control cities received standard care. The composite primary endpoint was infection of 
young adults with Chlamydia trachomatis, Trichomonas vaginalis, or Neisseria gonorrhoeae, or syphilis seroreactivity. 
Laboratory workers and the data analyst were masked, but ﬁ eldworkers, the Peruvian study team, and participants in 
the outcome surveys were not. All analyses were done by intention to treat. This trial is registered, 
ISRCTN43722548.
Findings We did baseline surveys of 15 261 young adults in 24 Peruvian cities. Of those, 20 geographically separate 
cities were matched into pairs, in each of which one city was assigned to intervention and the other to standard of 
care. In the 2006 follow-up survey, data for the composite primary outcome were available for 12 930 young adults. We 
report a non-signiﬁ cant reduction in prevalence of STIs in young adults, adjusted for baseline prevalence, in 
intervention cities compared with control cities (relative risk 0·84, 95% CI 0·69–1·02; p=0·096). In subgroup analyses, 
signiﬁ cant reductions were noted in intervention cities in young adult women and FSWs.
Interpretation Syndromic management of STIs, mobile-team outreach to FSWs, presumptive treatment for 
trichomoniasis in FSWs, and condom promotion might reduce the composite prevalence of any of the four curable 
STIs investigated in this trial. 
Funding Wellcome Trust and Burroughs Wellcome Fund, National Institutes of Health, Center for AIDS Research, 
CIPRA, and USAID-Peru.
Introduction
Many randomised trials have shown that interventions 
to reduce transmission or acquisition of sexually trans-
mitted infections (STIs) are eﬀ ective.1 Community-
random ised trials of STI prevention have used several 
approaches: strengthened STI syndrome management;2,3 
mass treat ment;4 community mobilisation, behaviour 
change, condom promotion and distribution, income-
generating projects, and clinic-based STI syndromic 
treatment;5 and sexual and reproductive health 
interventions for adolescents.6 These trials—in rural 
African settings—have had variable eﬀ ects on STI 
incidences. A neigh bourhood randomised intervention 
with peer opinion leaders used in ﬁ ve countries, 
including Peru, did not reduce STI prevalence in high-
risk populations.7
Longitudinal training of pharmacy workers in Peru has 
resulted in improvements in STI services,8,9 and 
longitudinal studies of clinic-based STI service improve-
ment for female sex workers (FSWs) have shown 
reductions in STI prevalences in FSW clinic attendees.10 
The eﬀ ect of such improvements on STI morbidity should 
be rigorously assessed at the population level (especially 
in urban settings). Additionally, feasibility assessments 
and results of multicomponent public health interventions 
are of growing importance. The Peru PREVEN Study 
targeted FSWs and the general population in Peruvian 
cities. We aimed to assess the eﬀ ect of the PREVEN 
intervention on community-level prevalences of four 
curable STIs (chlamydial infection, vaginal trichomoniasis, 
gonorrhoea, and syphilis), primarily in young adults and 
secondarily in FSWs.
For more on the Peru PREVEN 
study see http://www.
proyectopreven.org
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Methods
Study population
In accordance with the protocol, we identiﬁ ed cities in 
Peru with more than 50 000 inhabitants, and excluded 
those that were involved in another STI prevention trial. 
Geographically separate cities (classed as separate when 
more than 30 minutes travel by land between the cities) 
eligible for inclusion were matched into pairs that were 
randomly assigned to intervention or standard care.
Of 30 Peruvian cities with more than 50 000 inhabitants, 
we excluded Lima because its large population of 9 million 
precluded matching with another city, two cities because 
eﬀ ects could be altered by proximity to Lima, and three 
cities involved in another STI prevention trial,7 leaving 
24 cities. Population-based baseline surveys of young 
adults occurred from August to November, 2002 (table 1). 
We then selected 20 cities, matched them into pairs, and 
randomly assigned them to intervention or standard care. 
Outcome surveys in 2005 included random samples of 
young adults in these 20 cities. In 2006, a data and safety 
monitoring board recommended continuation of the 
interventions, with ﬁ nal outcome surveys in late 2006.
Baseline surveys in 2002, and subsequent outcome 
surveys in 2005 and 2006, were done in random 
household samples of young adults and in FSWs. Young 
adults aged 18–29 years who had lived in the city for 
6 months were eligible for inclusion in our analysis. 
For the baseline survey, we also did a comprehensive 
census of commercial sex venues. FSWs working at these 
venues, or attending screening clinics, were non-
randomly, consecutively selected until all venues had 
been visited or the quota of 200 FSWs per city was 
reached. Subsequent FSW surveys used sampling11 of 
individuals at randomly selected venues and times.
Institutional review boards at the University of 
Washington, Universidad Peruana Cayetano Heredia, 
and US Naval Medical Research Center Detachment 
approved the protocol, consent forms, and instruments. 
Eligible FSWs older than 14 years and survey participants 
provided verbal consent. All review boards exempted 
pharmacy workers and clinicians from informed 
consent. Young adult survey participants received study 
caps and T-shirts; FSW survey participants received 
free condoms.
Randomisation and masking
US and UK investigators (except JPH) were masked to 
identities of intervention cities until completion of all 
surveys and laboratory testing. Identiﬁ ed cities were paired 
based ﬁ rst on 2002 city-speciﬁ c composite STI prevalences 
in young adults, secondarily on region (coastal, Andean, 
or jungle), and thirdly on population size. Within each 
pair, one city was randomly assigned to an intervention 
with an S-PLUS (version 3·1) program written by JPH; the 
other city was assigned to standard care. Laboratory 
personnel and the data analyst (KKT) were masked to 
assignments until ﬁ nal analysis. Fieldworkers and the 
Peruvian study team could not be masked. Participants in 
outcome surveys were recruited after city randomisation, 
precluding allocation con cealment.
Procedures
All surveys of young adults used identical sampling 
methods, with paper questionnaires for the baseline 
survey and computer-assisted self-interviews with 
personal digital assistants in the later surveys.12 Men were 
asked to provide blood and urine samples, and women to 
provide blood and self-obtained vaginal swabs, or urine if 
unwilling to provide swabs. Participants received 
information about STIs and HIV, and referrals for test 
results, counselling, and treatment when indicated. 
FSWs answered face-to-face question naires in the 
baseline survey, followed by collection of blood and one 
endocervical and two vaginal swab specimens during 
speculum examination. All FSW participants completed 
questionnaires and provided three self-obtained vaginal 
swabs in 2005, and four in 2006.
After completion of a census of all pharmacies,  and of 
pharmacy workers, clinicians, and midwives in each city, 
the PREVEN network was created in intervention cities; 
STI training was undertaken for each group, involving 
STI syndromic management, and cross-referral of clients 
and patients across the network. Individuals who 
completed the programme of training were included in 
the network. Six key activities for improvement of 
syndromic management were adapted from our early 
programmes.8,9 First, workshops and materials were 
provided for pharmacy workers, emphasising recognition 
For the full Peru PREVEN 
protocol see http://www.
proyectopreven.org/portal/
index.php?Itemid=72
Start End
2002 general population baseline survey August, 2002 November, 2002
2005 general population survey September, 2005 December, 2005
2006 general population survey September, 2006 December, 2006
Client survey November, 2002 April, 2003
2002 FSW baseline survey November, 2002 April, 2003
2005 FSW survey September, 2005 December, 2005
2006 FSW survey September, 2006 December, 2006
PREVEN network intervention July, 2003 December, 2006
Mobile team intervention for FSWs July, 2003 December, 2006
Mobile team intervention for male sex workers April, 2006 December, 2006
Social marketing of condoms and treatment packets October, 2003 October, 2004
First health communication campaign October, 2003 October, 2004
Second health communication campaign April, 2005 August, 2005
Meeting of data and safety monitoring board April, 2006 April, 2006
Laboratory analyses for 2002 surveys January, 2003 December, 2003
Laboratory analyses for 2005 surveys January, 2007 March, 2006
Laboratory analyses for 2006 surveys January, 2007 April, 2008
Quality control of laboratory results June, 2006 May, 2009
Analysis of study outcome May, 2009 June, 2010
FSW=female sex worker.
Table 1: Timeline for the study
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of four STIs (male urethritis, vaginal discharge, genital 
ulcer disease, and pelvic inﬂ ammatory disease). Second, 
physicians and midwives were trained in STI syndromic 
management. Third, so-called prevention salespersons 
made monthly visits with educational materials to 
network members and pharmacy clients. Fourth, 
clinicians (including those certiﬁ ed by the network) were 
given a year 2 booster online STI course.13 Fifth, health-
communication campaigns for the general population 
were run in 2003–04, and in 2005, to improve recognition 
of STI symptoms and seeking of early appropriate STI 
health care. Finally, social marketing of low-cost condoms 
and inexpensive STI treatment packets for urethral 
discharge (containing ciproﬂ oxacin, 500 mg, and 
azithromycin, 1·0 g) and for vaginal discharge (containing 
metronidazole, 2·0 g) were placed in pharmacies in 
2003–04. Network training began in July, 2003, with all 
trainees certiﬁ ed by January, 2004. Prevention salesperson 
activities continued throughout 2006.
We created mobile teams and laboratory support 
systems in intervention cities to deliver clinical and 
preventive services to FSWs from July, 2003, to 
December, 2006. Each mobile team was made up of a 
nurse or midwife and an FSW peer educator. Mobile 
teams’ activities included two visits to each sex venue in 
each of 20 cycles of 8 weeks to provide periodic 
presumptive treatment14 with metronidazole for 
trichomoniasis and bacterial vaginosis to FSWs who were 
not pregnant or breastfeeding, and willing to forego 
alcohol consumption for 72 h. Self-obtained vaginal swabs 
were collected for local T vaginalis culture and for nucleic 
acid ampliﬁ cation in Lima for N gonorrhoeae and 
C trachomatis. The teams returned 1 week later, providing 
test results and treatment for speciﬁ c infections identiﬁ ed 
(ciproﬂ oxacin for gonorrhoea, azithromycin for chlamydia, 
and metronidazole for positive T vaginalis cultures not 
treated a week earlier). FSWs were encouraged to visit 
local government clinics for periodic syphilis and HIV 
testing, and for interim STI symptoms. Laboratory 
technicians joined mobile teams from February, 2005, to 
December, 2006, and did rapid syphilis testing.15
Separate mobile team outreach to male sex workers by 
a nurse or midwife and a peer occurred from April to 
December, 2006. Initial presumptive treatment was 1 g 
azithromycin for infection with C trachomatis and 500 mg 
oral ciproﬂ oxacin for N gonorrhoeae, with screening for 
syphilis and HIV. Seropositive male sex workers were 
referred to government clinics for care.
Mobile teams also provided motivational interviewing 
to promote condom use by sex workers, and gave up to 
15 condoms to each FSW in each 8 week cycle in the ﬁ rst 
1·5 years, then increased to 50 condoms per cycle. For 
the general population, the local non-governmental 
organisation APROPO imple mented social marketing of 
a low-cost condom, the OK condom, through pharmacies 
in intervention cities only, from October, 2003, to 
October, 2004, then more widely.
For all surveys, urine specimens, two polyester swab 
specimens stored in cryovials, and blood samples were 
promptly placed into coolers and transported to local 
laboratories. Trichomonas vaginalis culture media (InPouch, 
Biomed Diagnostics, White City, OR, USA) inoculated 
with cotton swabs were transported at ambient temperature 
to local laboratories. For the ﬁ rst survey, an additional 
swab was collected using the APTIMA Specimen 
Collection kit (Gen-Probe, San Diego, CA, USA). Serum, 
urine aliquots, and dry swabs in cryovials were frozen to 
−20°C at local laboratories and shipped weekly to Lima, 
where 1 mL of 2-sucrose-phosphate was added to each 
cryovial, and serological testing and nucleic acid 
ampliﬁ cation were done. Initial analysis of results 
identiﬁ ed a need for additional conﬁ rmatory testing for Figure 1: Study proﬁ le
2006 outcome survey
2105 FSWs eligible
7413 young adults eligible
2093 FSWs enrolled (range 200–222 per city)
6838 young adults enrolled (range 643–729 per city)
2092 FSWs provided biological samples
6509 young adults provided biological samples
2093 FSWs completed questionnaires
6822 young adults completed questionnaires
2006 outcome survey
2070 FSWs eligible
7426 young adults eligible
2063 FSWs enrolled (range 200–224 per city)
6945 young adults enrolled (range 628–882 per city)
2062 FSWs provided biological samples
6595 young adults provided biological samples
2063 FSWs completed questionnaires
6917 young adults completed questionnaires
24 cities assessed in 2002
16 867 young adults eligible
4483 FSWs enrolled (range 75–209 per city)
15 261 young adults enrolled (range 564–764 per city)
4465 FSWs provided biological samples
13 092 young adults provided biological samples
4413 FSWs completed questionnaires
15 260 young adults completed questionnaires
20 cities randomised
4 cities excluded
3 not geographically separate
1 did not have suitable city 
for comparison
10 control cities (median population size 
135 187, range 50 183–291 408)
10 intervention cities (median population size 
190 102, range 54 148–272 231)
2005 outcome survey
2023 FSWs eligible
8312 young adults eligible
2001 FSWs enrolled (range 176–217 per city)
8021 young adults enrolled (range 690–882 per city)
2001 FSWs provided biological samples
7341 young adults provided biological samples
1999 FSWs completed questionnaires
7905 young adults completed questionnaires
2005 outcome survey
2102 FSWs eligible
7962 young adults eligible
2083 FSWs enrolled (range 201–223 per city)
7626 young adults enrolled (range 687–889 per city)
2083 FSWs provided biological samples
6938 young adults provided biological samples
2083 FSWs completed questionnaires
7531 young adults completed questionnaires
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Chlamydia trachomatis and Neisseria gonorrhoeae infections 
because prevalences were high and inconsistent in some 
cities, and to improve N gonorrhoeae test speciﬁ city. 
Duplicate specimen collection allowed such testing. On 
the basis of the interim report from the data and safety 
monitoring board, nucleic acid ampliﬁ cation testing for 
T vaginalis was also added. Final analyses followed 
completion of these tests.
Baseline and 2005 detection of Chlamydia trachomatis 
was with Amplicor assays (Roche Diagnostics, NJ, USA). 
Indeterminate specimens were later tested by Aptima 
Combo 2 assay (Gen-Probe, San Diego, CA, USA). 
Results were counted as positive if Amplicor was positive, 
or if indeterminate and Aptima positive. The 2006 survey 
used Aptima assays. To exclude possible specimen 
contamination during collection or testing, positive tests 
were conﬁ rmed with concurrently collected urine or 
swab specimens suspended in 2-sucrose-phosphate.
For N gonorrhoeae, Amplicor assays were used for 
samples collected in the baseline survey. Positive 
specimens were later conﬁ rmed by Aptima Combo 
2 assay, with urine or swab samples suspended in 
2-sucrose-phosphate. In 2006, we deﬁ ned infection with 
N gonorrhoeae by positive Aptima results in initial 
specimens, with repeat conﬁ rmatory tests on concurrently 
collected specimens.
Culture specimens incubated at local laboratories 
were examined every day for 5 days for motile 
trichomonads. Urine and vaginal swabs collected during 
baseline and 2006 surveys were later tested in Lima with 
T vaginalis analyte-speciﬁ c reagents and Aptima General 
Purpose Reagents (Gen-Probe, San Diego, CA, USA).16 
Specimens consistently yielding relative light unit 
values of more than 100 000 were classed as positive. We 
counted specimens as positive for syphilis if they were 
seroreactive at titres of 1:8 or more by rapid-plasma-
reagin test and conﬁ rmed by Treponema pallidum particle 
agglutination assay. Specimens that twice tested positive 
on the enzyme-linked immunosorbent assay were 
conﬁ rmed by western blot assay in Lima; indeterminate 
specimens were retested at the University of Washington 
(Seattle, WA, USA).
Statistical analysis
The coeﬃ  cient of variation across cities in the 2002 young-
adult survey was 0·26 for the primary endpoint. Further 
calculations suggested matching could reduce this 
number to about 0·10.17 With ten city-pairs, 500 individuals 
sampled per city, and a composite STI prevalence of 
0·10 in the control group, we anticipated 90% power to 
detect a relative risk (RR) of 0·75 (α=0·05, two-tailed; 
formula 7·14).18 Similarly, 200 FSWs surveyed per city 
provided 87% power to detect a 30% reduction in the 
combined STI outcome, with the assumption of a control 
community prevalence of 14%. A data and safety 
monitoring board reviewed the trial in 2006, with an 
analysis that would stop the trial if the intervention was 
highly eﬀ ective (α <0·01) on the combined STI endpoint 
in both FSWs and young adults.
Continuous measures were summarised by medians 
and IQR, and categorical measures by proportions. The 
composite STI outcome for each participant was deﬁ ned 
as positive if any of the C trachomatis, N gonorrhoeae, 
vaginal T vaginalis (by GenProbe nucleic acid ampliﬁ cation 
tests), or syphilis seroreactivity results were positive; as 
negative if all were negative; and otherwise as missing. 
However, 563 missing syphilis serology values in young 
adults were classed as negative for composite endpoint 
calculation in the 2006 young adult survey (results were 
essentially unchanged by this classiﬁ cation).
The primary analysis of young adults regressed 
diﬀ erences in STI prevalence between intervention and 
control communities of the ith pair in 2006 outcome 
surveys against corresponding diﬀ erences in baseline 
surveys. In this regression, the intercept gives the 
adjusted diﬀ erence in prevalence between intervention 
and control communities in 2006. We tested the null 
hypothesis that the intercept was zero. Standard linear 
regression methods were used to ﬁ t the model and 
generate 95% CIs for adjusted risk diﬀ erences. We used 
one-way ANOVA to estimate intraclass correlation. We 
used generalised estimating equations with a log link to 
compute RR and 95% CIs, adjusted for city-speciﬁ c 
Figure 2: 20 cities selected for pair-wise randomisation to intervention and 
control groups
Circle sizes are proportionate to population sizes, which ranged from 50 183 to 
291 408. Total population size in intervention cities was 1 465 127, and in 
control cities 1 454 348. Lines connect city pairs.
Tumbes 
Talara 
Piura 
Cajamarca 
Iquitos 
Tarapoto 
Pucallpa 
Chimbote 
Huaraz 
Barranca 
Huanuco 
Cerro de Pasco 
Huancayo 
Chincha 
Ica 
Ayacucho Cuzco 
Juliaca 
Ilo 
Tacna 
200 000–300 000
150 000–200 000
100 000–150 000
50 000–100 000    
Population
Intervention
Control
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baseline prevalences with a modiﬁ ed approach19 to 
account for variance bias that can occur with few 
clusters. RR analyses do not incorporate information on 
pairing and are, therefore, conservative. Methods giving 
RR for paired data18,20 often failed to converge for rare 
infections; for consistency, we present unpaired RR 
analyses for all outcomes. All analyses were intention to 
treat. We did all statistical analyses with Stata 
(version 10·1). This study is registered, number 
ISRCTN43722548.
2002 survey 2006 survey
Control cities Intervention cities Control cities Intervention cities
Young adults
Total number enrolled 6307 6298 6945 6838
Men 3076 (48·8%) 3107 (49·3%) 3354 (48·5%)* 3346 (49·1%)*
Women 3231 (51·2%) 3191 (50·7%) 3559 (51·5%)* 3467 (50·9%)*
Median age (years) 22 (20–26) 22 (20–26) 22 (20–26) 23 (20–26)
<3 years residence in city 531 (8·4%) 538 (8·5%) 409 (5·9%) 419 (6·1%)
Region
Coast 3118 (49·4%) 2580 (41·0%) 3613 (52·0%) 2799 (40·9%)
Andes 1969 (31·2%) 2490 (39·5%) 1998 (28·8%) 2592 (37·9%)
Jungle 1220 (19·3%) 1228 (19·5%) 1334 (19·2%) 1447 (21·2%)
Education
Did not complete primary school 265 (4·2%) 267 (4·3%) 192 (2·8%) 195 (2·9%)
Completed primary school† 1327 (21·2%) 1216 (19·4%) 1210 (17·4%) 995 (14·6%)
Completed secondary school‡ 2186 (34·8%) 2222 (35·4%) 2551 (36·7%) 2393 (35·0%)
Beyond secondary school 2497 (39·8%) 2568 (40·9%) 2916 (42·0%) 3162 (46·2%)
Living with last sex partner 1690 (26·7%) 1629 (25·9%) 1981 (28·5%) 1986 (29·0%)
Ever had sex 4930 (81·8%) 4464 (75·7%) 5574 (82·0%) 5371 (79·9%)
Female participants
Report having had sex for money or gifts 117 (4·0%) 72 (2·5%) 83 (2·4%) 71 (2·1%)
Male participants
Sex with FSW in last year 465 (18·0%) 471 (18·2%) 538 (16·4%) 531 (16·3%)
Mean age of those who had been clients of FSW (years) 22·7 (3·1) 22·7 (3·4) 23·2 (3·4) 23·3 (3·4)
Sex with man in past year 165 (7·5%) 108 (4·9%) 136 (4·1%) 136 (4·1%)
FSW
Total number enrolled 1844 1888 2063 2093
Reporting a non-paying sex partner 922 (50·0%) 825 (43·7%) 912 (44·2%) 1335 (63·8%)
Living with non-client sex partner 517 (32·1%) 703 (41·0%) 571 (28·0%) 813 (40·0%)
Age (years) 24 (20–30) 25 (21–31) 23 (20–29) 25 (21–30)
Education
Did not complete primary school 208 (12·2%) 217 (12·4%) 222 (11·5%) 174 (8·8%)
Completed primary school† 709 (41·6%) 663 (37·9%) 828 (42·9%) 867 (43·7%)
Completed secondary school‡ 589 (34·6%) 621 (35·5%) 772 (40·0%) 776 (39·1%)
Beyond secondary school 197 (11·6%) 247 (14·1%) 109 (5·7%) 167 (8·4%)
Median nuevos soles charged last client 20 (15–50) 15 (10–35) 35 (20–70) 20 (10–78)
Place of work in past week
Brothel 290 (16·5%) 451 (23·4%) 293 (15·0%) 552 (26·0%)
Bar, night club, videopub, disco 1050 (59·6%) 1040 (56·3%) 1004 (51·6%) 1129 (53·3%)
Street 167 (9·5%) 201 (10·9%) 195 (10·0%) 246 (12·0%)
Other 214 (11·4%) 111 (5·6%) 369 (19·0%) 64 (3·1%)
More than one of above 42 (2·4%) 45 (2·4%) 54 (2·8%) 57 (2·7%)
Last vaginal sex with client unprotected 103 (6·8%) 122 (7·1%) 76 (4·0%) 67 (3·3%)
Last vaginal sex with non-paying partner unprotected§ 638 (69·2%) 562 (68·1%) 708 (77·6%) 908 (68·0%)
Data are n (%), median (IQR), or mean (SD). Percentages calculated on the basis of number of non-missing responses. Individuals aged 18–29 years are classed as young 
adults. FSW=female sex worker. *Sex was missing for 32 control and 25 intervention participants in the 2006 survey. †6 years of schooling. ‡11 years of schooling. 
§Sex without condom anytime in past 3 months with most recent non-paying partner. 
Table 2: Characteristics of the general-population and FSW participants at baseline and outcome surveys
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Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all 
data in the study; the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Baseline surveys of FSWs were done in the initial 24 cities 
(ﬁ gure 1), and then outcome surveys in the 20 randomised 
cities (ﬁ gure 2) in 2005, and in 2006. In baseline and ﬁ nal 
outcome surveys of young adults, more participants 
came from the coast in control cities than in intervention 
cities, and more came from the Andes in intervention 
cities other variables were similar (table 2). FSWs were 
older, and more lived with a sex partner and worked in 
brothels, in intervention cities than in control cities, but 
the median fee per client was lower; other variables were 
similar (table 2). Reported risk behaviours diﬀ ered little 
between intervention and control cities for young adults 
in 2006 (table 2). Proportion of FSWs reporting vaginal 
sex without condom use with last client or with a non-
paying partner did not diﬀ er signiﬁ cantly between 
intervention and control cities (table 2).
Proportion 
positive in 
control 
cities 
(2002)
Proportion 
positive in 
intervention 
cities (2002)
Proportion 
positive in 
control 
cities 
(2006)
Proportion 
positive in 
intervention 
cities (2006)
Mean 
diﬀ erence in 
2006 
prevalences 
(intervention–
control cities)
Adjusted 
diﬀ erence*
p value* RR (95% CI)†
All young adults (n=12 930)
Composite‡ 0·084 0·076 0·081 0·063 −0·018 −0·011 0·096 0·84 (0·69–1·02)
Chlamydia trachomatis 0·058 0·049 0·062 0·047 −0·015 −0·006 0·34 0·86 (0·70–1·05)
Neisseria gonorrhoeae 0·002 0·001 0·001 0·002 +0·0004 +0·0003 0·62 1·39 (0·41–4·77)
Trichomonas vaginalis 0·051 0·057 0·041 0·029 −0·013 −0·013 0·035 0·66 (0·48–0·92)
Syphilis seroreactive (titre ≥1:8) 0·005 0·005 0·003 0·002 −0·0002 −0·00001 0·99 1·08 (0·66–1·77)
Syphilis seroreactive (titre ≥1:16) 0·003 0·002 0·002 0·002 −0·0002 −0·00004 0·95 1·06 (0·47–2·36)
HIV 0·002 0·002 0·004 0·003 −0·001 −0·002 0·26 0·65 (0·32–1·30)
Young women (n=6556)
Composite 0·116 0·109 0·110 0·082 −0·030 −0·026 0·024 0·77 (0·61–0·96)
C trachomatis 0·071 0·060 0·075 0·055 −0·022 −0·015 0·12 0·79 (0·62–1·00)
N gonorrhoeae 0·002 0·000 0·002 0·002 −0·0004 −0·0006 0·56 0·62 (0·17–2·28)
T vaginalis 0·051 0·057 0·041 0·029 −0·013 −0·013 0·035 0·66 (0·48–0·92)
Syphilis seroreactive (titre ≥1:8) 0·004 0·004 0·002 0·002 −0·001 −0·001 0·44 0·72 (0·32–1·63)
Syphilis seroreactive (titre ≥1:16) 0·001 0·002 0·002 0·001 −0·001 −0·001 0·43 0·43 (0·10–1·81)
HIV 0·000 0·001 0·002 0·002 −0·0004 +0·001 0·62 1·10 (0·29–3·98)
Young men (n=6374)
Composite 0·050 0·042 0·051 0·044 −0·006 +0·004 0·58 1·00 (0·77–1·31)
C trachomatis 0·044 0·037 0·048 0·040 −0·008 −0·002 0·71 0·94 (0·72–1·23)
N gonorrhoeae 0·001 0·002 0·0003 0·002 +0·001 +0·001 0·33 3·65 (0·16–81·2)
T vaginalis 0·003 0·003 0·004 0·003 −0·001 −0·001 0·63 0·82 (0·36–1·89)
Syphilis seroreactive (titre ≥1:8) 0·006 0·005 0·003 0·003 +0·001 +0·001 0·66 1·39 (0·50–3·86)
Syphilis seroreactive (titre ≥1:16) 0·005 0·003 0·002 0·003 +0·001 +0·001 0·50 1·72 (0·45–6·55)
HIV 0·003 0·004 0·006 0·005 −0·001 −0·002 0·22 0·74 (0·38–1·42)
Female sex workers (n=4130)
Composite 0·215 0·212 0·221 0·145 −0·075 −0·074 0·023 0·66 (0·47–0·94)
C trachomatis 0·155 0·138 0·145 0·099 −0·045 −0·037 0·082 0·72 (0·54–0·98)
N gonorrhoeae 0·024 0·012 0·010 0·007 −0·003 −0·007§ 0·026§ 1·44 (0·02–122)§
T vaginalis 0·074 0·097 0·086 0·045 −0·042 −0·053 0·0048 0·49 (0·32–0·75)
Syphilis seroreactive (titre ≥1:8) 0·016 0·012 0·011 0·014 +0·003 +0·003 0·32 1·32 (0·79–2·20)
Syphilis seroreactive (titre ≥1:16) 0·007 0·006 0·007 0·008 +0·001 +0·001 0·72 1·12 (0·67–1·89)
HIV 0·007 0·008 0·005 0·003 −0·002 −0·002 0·51 0·49 (0·10–2·54)
Overall numbers are from the 2006 surveys. Proportions calculated on the basis of how many individuals provided biological specimens that were adeqaute for testing. 
Individuals aged 18–29 years are classed as young adults. *From linear regression on diﬀ erences between paired cities in 2006, adjusted for diﬀ erences in 2002. †Adjusted for 
2002 prevalences, but not for pairing; CIs computed with method of Pan and Wall.19 ‡Includes T vaginalis in women only, per original analysis plan. §Adjusted results for 
N gonorrheae in female sex workers are very sensitive to the model used.
Table 3: Prevalence of sexually transmitted infections in control and intervention cities
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In intervention cities, we trained and certiﬁ ed workers 
at 623 (80·6%) of 773 pharmacies, and 701 (69·6%) of 
1007 physicians and midwives in private practice. We 
continued training new pharmacy workers and clinicians 
coming to these cities. Pharmacies in intervention cities 
reported 290 440 visits for STI-related symptoms in 
2004–06; clinicians reported 184 208. Substantial, sus-
tained improvements in syndromic management in 
intervention cities were noted after 7280 simulated-
patient visits to pharmacies in the 20 cities at baseline 
and at 3, 6, and 18 months thereafter (data not shown).
Mobile teams in ten intervention cities interviewed 
FSWs 48 207 times during 20 8-week cycles. Numbers of 
venues and FSWs visited per cycle increased by more 
than 50% in the ﬁ rst year, but then stabilised (data not 
shown). In the 2005 surveys, young adult survey 
participants in intervention cities reported exposure to 
the campaign messages about STIs and condoms more 
and reported unprotected sex with a casual partner less 
often than did those in control cities (data not shown). 
Women in intervention cities sought appropriate care for 
STI-related symptoms more often than those in control 
cities (data not shown).
In 2006, data for the composite primary outcome were 
available for 12 930 (98·7%) of 13 104 young adults 
providing samples (6374 men and 6556 women). The 
adjusted composite STI prevalence in young men and 
women was an absolute 1·1% lower, adjusted for baseline 
prevalence, in intervention cities than in control cities 
(p=0·096; table 3). In ancillary analysis limited to the 
young women, 268 (8·2%) of 3259 women had any STI 
in intervention cities compared with 364 (11·0%) of 
3297 in control cities (absolute risk reduction 2·6%, 
p=0·024; table 3). For young men, by contrast, 141 (4·4%) 
of 3189 in intervention cities and 161 (5·1%) of 3185 in 
control cities had any STI; the adjusted diﬀ erence in 
composite prevalence of curable STIs between study 
groups was negligible (table 3). However, in 2006, the 
prevalence of C trachomatis in men who had had sex with 
FSWs in the past year was 7·2% in control cities and 
3·5% in intervention cities (adjusted RR 0·68, 95% CI 
0·28–1·68). The (unmatched) intraclass correlation for 
the composite STI prevalence (men and women) in the 
intervention communities was 0·0016 (95% CI 0·00–
0·0046) and in the control communities 0·0088 (95% CI 
0·00–0·018).
In 2006, STI prevalences were available for 
4130 (99·4%) of 4156 enrolled FSWs. 302 (14·5%) of 
2085 FSWs had any STI in intervention cities compared 
with 451 (22·1%) of 2045 in control cities (table 3). 
Adjustment for composite baseline prevalences gave a 
7·4% lower absolute risk in intervention than in control 
cities in 2006 (p=0·023; table 3). Prevalences of 
C trachomatis, T vaginalis, and N gonorrhoeae infections 
declined in intervention cities (table 3). Syphilis sero-
prevalence was not signiﬁ cantly diﬀ erent in intervention 
and control cities (table 3). HIV prevalences were low, 
without signiﬁ cant diﬀ erences between control and 
intervention cities (table 3). The (unmatched) intraclass 
correlation for the composite STI prevalence in 
intervention FSW communities was 0·046 (95% CI 
0·00–0·092), and in control communities 0·023 (95% CI 
0·00–0·050). In young women and FSW, any diﬀ erences 
in rates of infection with C trachomatis in each population 
in 2005, were similar to those recorded in 2006, indicating 
that intervention eﬀ ects in these groups were consistent 
and evident within 2 years.
Discussion
After 3 years of interventions, the prevalence of any of 
four curable STIs in young adults was lower in 
intervention cities than in control cities, although this 
diﬀ erence was not signiﬁ cant. The diﬀ erence was 
signiﬁ cant in young women, but not in young men. 
Additionally, FSWs in intervention cities had signiﬁ cantly 
lower prevalence of STIs. As far as we are aware, this is 
the ﬁ rst urban community randomised trial to show an 
intervention might reduce prevalences of curable STIs in 
young women and FSWs (panel).
Although the eﬀ ect in FSWs was consistent with 
projections, results in young adults were not as expected. 
We anticipated that FSW screening and treatment could 
help to lower STI prevalences in young men, because 
data have implicated that unprotected sex with FSWs is 
the major risk factor for STIs in men in Lima.25 We 
predicted that prevalence of STIs would fall in young 
women because of reduced prevalence in male clients. 
We observed no overall reduction of STIs in young men, 
although our 2006 survey did show that prevalence of 
C trachomatis was lower in those who reported sex with 
FSWs in the past year in intervention than in control 
cities. The eﬀ ect of interventions in women, especially 
on trichomoniasis, could be because they sought 
appropriate care for STI-related symptoms more than did 
men. For example, many more women were treated for 
vaginal discharge in 2004–06 in intervention cities than 
were men for urethral discharge.
Movement of FSWs between cities, and infrequent use 
of condoms with non-client partners, probably restricted 
the eﬀ ect of interventions in this population. The high 
rate of condom use reported by FSWs in control cities in 
2006 meant further improvement in intervention cities 
would be diﬃ  cult. In 2005, surveys reached 2–10% of 
young adults (dependent on city size) but higher 
proportions of FSWs. Treatment of infected FSWs in 
2005 surveys could have attenuated 2006 survey 
diﬀ erences in FSWs in control and intervention cities.
Our study had several strengths: detailed preliminary 
studies;8–10 widespread community engagement;8–10 
cluster-randomised design with pair-wise matching and 
adjustment for baseline prevalences; inclusion of three 
disparate geographic regions in Latin America, 
(a neglected area); many evidence-based intervention 
components, with structural and technical components 
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for both high-risk and general populations; use and 
strengthening of existing health systems; collaborations 
with local partners; and use of personal digital assistants 
for collection of conﬁ dential data. The focus on urban 
populations is important in view of worldwide trends in 
urbanisation and concentrations of STIs in cities.
A trade-oﬀ  exists between internally valid trials of 
simple interventions and trials of multicomponent 
interventions adapted to local contexts.26 When a one-
component intervention has no beneﬁ t, whether 
complementary or synergistic components would have 
added beneﬁ t is unknown. By contrast, the challenge 
with multicomponent or complex interventions27–30 is 
identiﬁ cation of components contributing most to 
success. Further study limitations were the cross-
sectional rather than cohort-based outcome measures, 
remarkable mobility of FSWs, and changes to nucleic 
acid ampliﬁ cation testing protocols. Overall, this 
prevention package was feasible, acceptable, and had a 
moderate eﬀ ect on curable STI prevalences. Although 
our study was broadly inclusive of high-risk populations 
and the general public, and used the existing health-
care system, the generalisability is unknown and the 
cost-eﬀ ectiveness of these intervention components are 
to be established. 
Panel: Research in context
Systematic review
A systematic review1 had previously identiﬁ ed 74 late-phase randomised controlled trials of interventions to prevent sexually transmitted infections (STIs) 
other than HIV reported before the end of 2009. Of these studies, three cluster randomised trials2,3,5 used syndromic management and measured STI rates and 
HIV incidence. The multicomponent community randomised trial in Masaka, Uganda,2 compared a control group with a behaviour-change intervention, with or 
without improved STI syndromic management. The behaviour-change intervention signiﬁ cantly lowered incidence of infection with herpes simplex virus 2, 
and the combined intervention signiﬁ cantly reduced incidence of syphilis (rapid-plasma-reagin titre ≥1:8) and gonorrhoea prevalence. Prevalence of Chlamydia 
trachomatis was not aﬀ ected, and Trichomonas vaginalis was not assessed. In the Tanzanian trial of improved STI syndromic management,3 the adjusted relative 
risk in intervention versus control cities for syphilis seroprevalence (rapid-plasma-reagin titre ≥1:8) in adult cohorts was 0·71 (95% CI 0·54–0·93) after 2 years. 
Prevalence of urethral infection with Neisseria gonorrhoeae or C trachomatis was not signiﬁ cantly lowered. After 2 years, prevalences of any curable STI in 
antenatal women (N gonorrhoeae, C trachomatis, T vaginalis, or active syphilis) were similar in intervention and control communities. The Zimbabwean trial5 
showed no eﬀ ect on STIs.5
A 2008 review of HIV and STI prevention interventions in female sex workers (FSWs) in resource-poor settings21 identiﬁ ed 28 interventions with follow-ups of 
more than 6 months and externally measureable outcomes. Overall, evidence suggested that multicomponent interventions can reduce HIV and STI acquisition 
in FSWs, as can structural interventions (eg, required condom use in Thai brothels). However, only two cluster randomised trials showed STI outcomes. Of those, 
one unpublished study with two cycles of presumptive antimicrobial treatment showed no signiﬁ cant eﬀ ect on gonorrhoea or chlamydial infection. A second 
showed that when FSWs were given the option of female condoms, aggregate STI risk was not signiﬁ cantly aﬀ ected.22
India’s Avahan project is an important non-randomised multicomponent prevention programme targeting high-risk populations to decrease population-level 
spread of HIV and other STIs.23,24 Although reductions in HIV prevalence were associated with intervention intensity in three of six states,23 a separate 
commentary24 concluded that only with a prospective, robust assessment of the programme’s implementation could the investigators have convincingly 
proven eﬀ ectiveness.
Interpretation
How few cluster-randomised controlled trials of multicomponent interventions to reduce transmission of curable STIs exist, especially in urban settings, is 
remarkable. None have shown an eﬀ ect on C trachomatis or T vaginalis, the two most common curable STIs. This study used a multicomponent intervention 
adapted to high-risk and general-population groups. Our primary outcome analysis provided weak evidence at best for a reduction in curable STIs in young 
adults. However, secondary and ancillary analyses did show signiﬁ cant reductions in young women and FSWs, largely due to reductions in C trachomatis and T 
vaginalis infection. The trial revealed important context-speciﬁ c challenges and opportunities, such as FSW mobility, potential for interventions for male sex 
workers, potential of pharmacy-based interventions, and eﬀ ects of condom social marketing and of health-communication campaigns.
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